Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression

Journal of Women's Health

Volumn 12, Issue 1, 2003, Pages 33-39

  Berlanga, Carlos ^a   Mendieta, Danelia ^a   Alva, Guadalupe ^a   Del Carmen Lara, María ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FLUOXETINE; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TIBOLONE;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOOD; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037275176     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/154099903321154121     Document Type: Article

References (31)

1. Kessler RC, McGonagle K, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51:8.
2. Kornstein S. Gender differences in presentation of chronic major depression. Psychopharmacol Bull 1995; 31:711.
3. Zlotnick C, Shea M, Pilkonis P, et al. Type of treatment, dysfunctional attitudes, social support, life events and depressive symptoms over naturalistic follow-up. Am J Psychiatry 1996;153:1021.
4. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992;149:587.
5. Rubinow D, Roy-Byrne P. Premenstrual syndromes: Overview from a methodological perspective. Am J Psychiatry 1984;141:163.
6. Frank E, Kupfer D, Jacob M, et al. Pregnancy-related affective episodes among women with recurrent depression. Am J Psychiatry 1987;144:288.
7. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey: Lifetime prevalence, chronicity and recurrence. J Affective Disord 1993;29:85.
8. Frank E. Gender and its effects on psychopathology. Washington, DC: American Psychiatric Association Press, 2000.
9. Schmidt PJ, Nierman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: A preliminary report. Am J Obstet Gynecol 2000; 183:414.
10. Sherwin BB. Affective changes in estrogen and androgen replacement therapy in surgically menopausal women. J Affective Discord 1988;14:177.
11. Zwerfel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997;22:189.
12. Yang NN, Venugopalan M, Hardikar S, Gasebrook A. Identification of an estrogen response element activated by metabolites of 17-beta estradiol and raloxifene. Science 1996;273:1222.
13. O'Mailey BW, Means AR. Female steroid hormone and target cell nuclei. Science 1993;183:610.
14. Naftolin F, ed. Ovarian secretion and cardiovascular and neurological functions. New York: Raven Press, 1990.
15. Duman RS, Heninger CR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597.
16. Sthal SM. Essential psychopharmacology. New York: Cambridge University Press, 2000.
17. Schneider KS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and the response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997;5:97.
18. de Novaes Soares C, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529.
19. Holte A. Menopause, mood and hormone replacement therapy: Methodological issues. Maturitas 1998; 30:798.
20. Albertazzi P, Di Micco R, Zanardi E. Tibolone: A review. Maturitas 1998;30:295.
21. Kloosterboer HJ. Tibolone, a steroid with a tissue specific mode of action. J Steroid Biochem Mol Biol 2001; 76:231.
22. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279.
23. Stahl SM. Sex and psychopharmacology. Is natural estrogen a psychotropic drug in women? Arch Gen Psychiatry 2001;58:537.
24. Albertazzi P, Natale V, Barbolini C, Teglio L, Di Micco R. The effect of tibolone vs. continuous combined norethisterone acetate and oestradiol on memory, libido and mood of postmenopausal women: A pilot study. Maturitas 2000;36:223.
25. Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: An overview. J Clin Psychiatry 1998;59 (Suppl 5):5.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1995.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56.
28. Guy W. ECDEU. Assessment manual for psychopharmacology. U.S. Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976:218.
29. Greene JG. Guide to the Greene climacteric scale. Glasgow: University of Glasgow, 1991.
30. SPSS statistical package for social sciences, version 8.0 for Windows (computer program). Chicago, IL: SPSS Inc, 1997.
31. Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and women: Sex, gender and hormones. Washington, DC: American Psychiatric Press Inc, 1996.